Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Mallinckrodt
McKesson
AstraZeneca
Johnson and Johnson

Last Updated: August 15, 2022

Investigational Drug Information for MLN9708


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug MLN9708?

MLN9708 is an investigational drug.

There have been 85 clinical trials for MLN9708. The most recent clinical trial was a Phase 3 trial, which was initiated on September 20th 2017.

The most common disease conditions in clinical trials are Multiple Myeloma, Neoplasms, Plasma Cell, and Lymphoma. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and Mayo Clinic.

There are thirty-seven US patents protecting this investigational drug and three hundred and forty-seven international patents.

Recent Clinical Trials for MLN9708
TitleSponsorPhase
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain AmyloidosisNational Cancer Institute (NCI)Phase 1
Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM TrialNational Cancer Institute (NCI)Phase 3
Trial of Ixazomib for Kaposi SarcomaNational Cancer Institute (NCI)Phase 2

See all MLN9708 clinical trials

Clinical Trial Summary for MLN9708

Top disease conditions for MLN9708
Top clinical trial sponsors for MLN9708

See all MLN9708 clinical trials

US Patents for MLN9708

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MLN9708 See Plans and Pricing Proteasome inhibition assay and methods of use Beckman Coulter, Inc. (Brea, CA) University Health Network (Toronto, CA) See Plans and Pricing
MLN9708 See Plans and Pricing Glycolipid containing compositions for use in the treatment of tumors Agalimmune Limited (GB) See Plans and Pricing
MLN9708 See Plans and Pricing Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) See Plans and Pricing
MLN9708 See Plans and Pricing Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS AG (Basel, CH) See Plans and Pricing
MLN9708 See Plans and Pricing Pyrrolcarboxamide derivatives for the inhibition of ERK5 See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MLN9708

Drugname Country Document Number Estimated Expiration Related US Patent
MLN9708 European Patent Office EP3058086 2033-10-18 See Plans and Pricing
MLN9708 European Patent Office EP3360969 2033-10-18 See Plans and Pricing
MLN9708 World Intellectual Property Organization (WIPO) WO2015057402 2033-10-18 See Plans and Pricing
MLN9708 Australia AU2015257496 2034-05-09 See Plans and Pricing
MLN9708 Canada CA2948439 2034-05-09 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Mallinckrodt
McKesson
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.